Lower vancomycin trough levels in adults undergoing unrelated cord blood transplantation

References

• Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351(22):2265–2275.
   PubMed Web of Science ®Google Scholar
• Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351(22):2276–2285.
   PubMed Web of Science ®Google Scholar
• Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653–660.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):427–431.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2005;5(7):431–439.
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82–98.
   PubMedGoogle Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–292.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Tokimatsu I, Morinaga Y, et al. A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy. Clin Chim Acta. 2015;440:183–187.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507–514.
   PubMed Web of Science ®Google Scholar
• Okada N, Chuma M, Azuma M, et al. Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study. Eur J Clin Pharmacol. 2019;75(12):1695–1704.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734–744.
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Joo J, Tse E, et al. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents. 2011;37(2):95–101.
   PubMed Web of Science ®Google Scholar
• Mae H, Ooi J, Takahashi S, et al. Acute kidney injury after myeloablative cord blood transplantation in adults: the efficacy of strict monitoring of vancomycin serum trough concentrations. Transpl Infect Dis. 2013;15(2):181–186.
   PubMed Web of Science ®Google Scholar
• Ghehi MT, Rezaee S, Hayatshahi A, et al. Vancomycin pharmacokinetic parameters in patients undergoing Hematopoietic Stem Cell Transplantation (HSCT). Int J Hematol Oncol Stem Cell Res. 2013;7(4):1–9.
   PubMedGoogle Scholar
• Okada A, Kariya M, Irie K, et al. Population pharmacokinetics of vancomycin in patients undergoing allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Pharmacol. 2018;58(9):1140–1149.
   PubMed Web of Science ®Google Scholar
• Clemmons AB, Bech CF, Pantin J, et al. Acute kidney injury in hematopoietic cell transplantation patients receiving vancomycin and piperacillin/tazobactam versus vancomycin and cefepime. Biol Blood Marrow Transplant. 2018;24(4):820–826.
   PubMed Web of Science ®Google Scholar
• Konuma T, Kato S, Oiwa-Monna M, et al. Cryopreserved CD34+ cell dose, but not total nucleated cell dose, influences hematopoietic recovery and extensive chronic graft-versus-host disease after single-unit cord blood transplantation in adult patients. Biol Blood Marrow Transplant. 2017;23(7):1142–1150.
   PubMed Web of Science ®Google Scholar
• Yanada M, Konuma T, Kuwatsuka Y, et al. Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. Bone Marrow Transplant. 2019;54(11):1789–1798.
   PubMed Web of Science ®Google Scholar
• Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–c184.
   PubMedGoogle Scholar
• Baptista JP, Udy AA, Sousa E, et al. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care. 2011;15(3):R139.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
   PubMed Web of Science ®Google Scholar
• Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367–369.
   PubMed Web of Science ®Google Scholar
• Konuma T, Kato S, Ooi J, et al. Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission. Biol Blood Marrow Transplant. 2014;20(3):396–401.
   PubMed Web of Science ®Google Scholar
• Konuma T, Kato S, Oiwa-Monna M, et al. Single-unit cord blood transplant for acute lymphoblastic leukemia and lymphoma using an intensified conditioning regimen of total body irradiation, high-dose cytarabine and cyclophosphamide. Leuk Lymphoma. 2015;56(4):1148–1150.
   PubMed Web of Science ®Google Scholar
• Choi MH, Choe YH, Lee SG, et al. Neutropenia is independently associated with sub-therapeutic serum concentration of vancomycin. Clin Chim Acta. 2017;465:106–111.
   PubMed Web of Science ®Google Scholar
• Izumisawa T, Kaneko T, Soma M, et al. Augmented renal clearance of vancomycin in hematologic malignancy patients. Biol Pharm Bull. 2019;42(12):2089–2094.
   PubMed Web of Science ®Google Scholar
• Hirai K, Ishii H, Shimoshikiryo T, et al. Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin. Ther Drug Monit. 2016;38:706–710.
   PubMed Web of Science ®Google Scholar
• Fujikura Y, Hamamoto T, Kanayama A, et al. Bayesian reconstruction of a vancomycin-resistant Enterococcus transmission route using epidemiologic data and genomic variants from whole genome sequencing. J Hosp Infect. 2019;103(4):395–403.
   PubMed Web of Science ®Google Scholar
• Mizusawa M, Konuma T, Kato S, et al. Clinical outcomes of persistent colonization with multidrug-resistant Gram-negative rods in adult patients undergoing single cord blood transplantation. Int J Hematol. 2020;111(6):858–868.
   PubMed Web of Science ®Google Scholar
• Haeseker MB, Croes S, Neef C, et al. Vancomycin dosing in neutropenic patients. PLoS One. 2014;9(11):e112008.
   PubMed Web of Science ®Google Scholar
• Pritchard L, Baker C, Leggett J, et al. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010;123(12):1143–1149.
   PubMed Web of Science ®Google Scholar
• Gutgarts V, Sathick IJ, Zheng J, et al. Incidence and risk factors for acute and chronic kidney injury after adult cord blood transplantation. Biol Blood Marrow Transplant. 2020;26(4):758–763.
   PubMed Web of Science ®Google Scholar
• Yasu T, Konuma T, Oiwa-Monna M, et al. Efficacy and safety of low-dose liposomal amphotericin b in adult patients undergoing unrelated cord blood transplantation. Antimicrob Agents Chemother. 2018;62(11):e01205.
   PubMed Web of Science ®Google Scholar
• Konuma T, Oiwa-Monna M, Mizusawa M, et al. Early fluid overload predicts higher non-relapse and overall mortality in adults after single-unit cord blood transplantation. Bone Marrow Transplant. 2019;54(12):2096–2101.
   PubMed Web of Science ®Google Scholar
• Stanzani M, Vianelli N, Cavo M, et al. Retrospective cohort analysis of liposomal amphotericin B nephrotoxicity in patients with hematological malignancies. Antimicrob Agents Chemother. 2017;61(9):e02651.
   PubMed Web of Science ®Google Scholar
• Wilson JF, Davis AC, Tobin CM. Evaluation of commercial assays for vancomycin and aminoglycosides in serum: a comparison of accuracy and precision based on external quality assessment. J Antimicrob Chemother. 2003;52(1):78–82.
   PubMed Web of Science ®Google Scholar
• Shipkova M, Petrova DT, Rosler AE, et al. Comparability and imprecision of 8 frequently used commercially available immunoassays for therapeutic drug monitoring. Ther Drug Monit. 2014;36(4):433–441.
   PubMed Web of Science ®Google Scholar
• Neely MN, Kato L, Youn G, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2017;62(2):e02042.
   Web of Science ®Google Scholar